2021 国际共识:无症状SDHx基因突变携带者的初始筛查和随访

2021-05-21 国外肿瘤科相关专家小组(统称) Nat Rev Endocrinol.2021 May 21.

被诊断为嗜铬细胞瘤或副神经节瘤患者中约有20%携带SDHx基因突变,当在患者中发现致病性SDHx基因突变时,推荐为其一级亲属进行遗传性咨询。本文主要针对无症状SDHx基因突变携带者的初始筛查和随访提供

中文标题:

2021 国际共识:无症状SDHx基因突变携带者的初始筛查和随访

英文标题:

International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers

发布日期:

2021-05-21

简要介绍:

被诊断为嗜铬细胞瘤或副神经节瘤患者中约有20%携带SDHx基因突变,当在患者中发现致病性SDHx基因突变时,推荐为其一级亲属进行遗传性咨询。本文主要针对无症状SDHx基因突变携带者的初始筛查和随访提供指导建议。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 国际共识:无症状SDHx基因突变携带者的初始筛查和随访.pdf)] GetToolGuiderByIdResponse(projectId=1, id=f68d81c002110357, title=2021 国际共识:无症状SDHx基因突变携带者的初始筛查和随访, enTitle=International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers, guiderFrom=Nat Rev Endocrinol.2021 May 21., authorId=0, author=, summary=被诊断为嗜铬细胞瘤或副神经节瘤患者中约有20%携带SDHx基因突变,当在患者中发现致病性SDHx基因突变时,推荐为其一级亲属进行遗传性咨询。本文主要针对无症状SDHx基因突变携带者的初始筛查和随访提供, cover=https://img.medsci.cn/2021530/1622305748494_2020535.jpg, journalId=0, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Fri May 21 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>被诊断为嗜铬细胞瘤或副神经节瘤患者中约有20%携带SDHx基因突变,当在患者中发现致病性SDHx基因突变时,推荐为其一级亲属进行遗传性咨询。本文主要针对无症状SDHx基因突变携带者的初始筛查和随访提供指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=11634, tagName=嗜铬细胞瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=11634, guiderKeyword=嗜铬细胞瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=9417, appHits=86, showAppHits=0, pcHits=569, showPcHits=9330, likes=1, shares=24, comments=6, approvalStatus=1, publishedTime=Sun May 30 00:29:37 CST 2021, publishedTimeString=2021-05-21, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun May 30 00:29:26 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 20:12:43 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 国际共识:无症状SDHx基因突变携带者的初始筛查和随访.pdf)])
2021 国际共识:无症状SDHx基因突变携带者的初始筛查和随访.pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=973547, encodeId=3b339e35476c, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e8a5480521, createdName=ms8000000656093431, createdTime=Mon Jun 14 20:43:37 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973540, encodeId=ba979e354017, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e8a5480521, createdName=ms8000000656093431, createdTime=Mon Jun 14 20:38:49 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970669, encodeId=70d79e066957, content=特别好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bac75444492, createdName=ms8000000167910564, createdTime=Thu Jun 03 19:33:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969945, encodeId=943d9699459d, content=写的真好!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa795510567, createdName=ms7000000927586640, createdTime=Mon May 31 21:31:49 CST 2021, time=2021-05-31, status=1, ipAttribution=)]
    2021-06-14 ms8000000656093431

    感谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=973547, encodeId=3b339e35476c, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e8a5480521, createdName=ms8000000656093431, createdTime=Mon Jun 14 20:43:37 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973540, encodeId=ba979e354017, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e8a5480521, createdName=ms8000000656093431, createdTime=Mon Jun 14 20:38:49 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970669, encodeId=70d79e066957, content=特别好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bac75444492, createdName=ms8000000167910564, createdTime=Thu Jun 03 19:33:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969945, encodeId=943d9699459d, content=写的真好!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa795510567, createdName=ms7000000927586640, createdTime=Mon May 31 21:31:49 CST 2021, time=2021-05-31, status=1, ipAttribution=)]
    2021-06-14 ms8000000656093431

    感谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=973547, encodeId=3b339e35476c, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e8a5480521, createdName=ms8000000656093431, createdTime=Mon Jun 14 20:43:37 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973540, encodeId=ba979e354017, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e8a5480521, createdName=ms8000000656093431, createdTime=Mon Jun 14 20:38:49 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970669, encodeId=70d79e066957, content=特别好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bac75444492, createdName=ms8000000167910564, createdTime=Thu Jun 03 19:33:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969945, encodeId=943d9699459d, content=写的真好!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa795510567, createdName=ms7000000927586640, createdTime=Mon May 31 21:31:49 CST 2021, time=2021-05-31, status=1, ipAttribution=)]
    2021-06-03 ms8000000167910564

    特别好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=973547, encodeId=3b339e35476c, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e8a5480521, createdName=ms8000000656093431, createdTime=Mon Jun 14 20:43:37 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973540, encodeId=ba979e354017, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e8a5480521, createdName=ms8000000656093431, createdTime=Mon Jun 14 20:38:49 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970669, encodeId=70d79e066957, content=特别好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bac75444492, createdName=ms8000000167910564, createdTime=Thu Jun 03 19:33:23 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969945, encodeId=943d9699459d, content=写的真好!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa795510567, createdName=ms7000000927586640, createdTime=Mon May 31 21:31:49 CST 2021, time=2021-05-31, status=1, ipAttribution=)]
    2021-05-31 ms7000000927586640

    写的真好!

    0

拓展阅读

嗜铬细胞瘤和副神经节瘤诊断治疗的专家共识

中华医学会内分泌学分会(CSE,Chinese Society of Endocrinology) · 2016-04-02

2020 ESMO/EURACAN临床实践指南:肾上腺皮质癌和恶性嗜铬细胞瘤的诊断,治疗以及随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2020-08-24

嗜铬细胞瘤和副神经节瘤诊断治疗专家共识(2020版)

中华医学会内分泌学分会(CSE,Chinese Society of Endocrinology) · 2020-09-30

《嗜铬细胞瘤和副神经节瘤诊断治疗专家共识(2020版)》解读

福建医科大学附属第一医院全科医学科福建省高血压研究所 · 2021-08-15